傲農生物(603363.SH):以1.71億元競得閩侯經開區相關工業用地 在福州佈局生豬屠宰業務
格隆匯5月29日丨傲農生物(603363.SH)公佈,近日,公司以總價人民幣1.71億元競得標的土地使用權並簽署《國有建設用地使用權掛牌成交確認書》,宗地坐落於閩侯經濟技術開發區三期,宗地總面積為20936平方米(合31.4畝),土地用途為工礦倉儲用地一工業用地(農副食品加工業--屠宰場),出讓年限50年,容積率為1.2≤容積率≤2.0,建築密度為30%≤建築密度≤45%。
公司以“飼料、養豬、食品”為主業,在福建省內多地已佈局了生豬養殖基地,並已在廈門、泉州開展屠宰食品業務,通過此次競得土地使用權在福州市佈局生豬屠宰業務,符合公司向“農牧食品企業”發展的戰略規劃,對促進公司率先在福建省內實現產業鏈一體化發展、形成和打造產業鏈模式並未來向其他生豬養殖區域複製拓展,及進一步夯實公司市場競爭力具有重要戰略意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.